Mixed trend on the daily chart: above its 200-day average, below its 50-day · 50-day above the 200-day · SuperTrend down since Sep 25 · below the Ichimoku cloud · RSI 41 · MACD below its signal
| 29.27 | 52-week high | +55.43% |
| 25.19 | Previous month high | +33.74% |
| 22.24 | Previous week high | +18.08% |
| 19.63 | R3 (classic) | +4.20% |
| 19.60 | Previous week low | +4.06% |
| 19.55 | Previous month low | +3.80% |
| 19.17 | R2 (classic) | +1.80% |
| 18.84 | Price now | |
| 18.72 | Previous day high | −0.61% |
| 18.59 | R1 (classic) | −1.32% |
| 18.13 | Pivot | −3.73% |
| 17.68 | Previous day low | −6.13% |
| 17.55 | S1 (classic) | −6.84% |
| 17.09 | S2 (classic) | −9.25% |
| 16.51 | S3 (classic) | −12.36% |
| 5.55 | 52-week low | −70.53% |
None of the 29 investors followed here reported a position in NVCT in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a NVCT trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Aug 2, 2026 | Carson Michael J.Officer | Stock Award(Grant) at price 0.00 per share. | 30K | — |
| Jun 29, 2026 | Bentsur RonChief Executive Officer | Purchase at price 20.00 per share. | 12.5K | $250.00K |
| Jun 29, 2026 | Mosseri Marlio CharlesBeneficial Owner of more than 10% of a Class of Security | Purchase at price 18.32 per share. | 50K | $916.00K |
| Jun 10, 2026 | Oliviero James F IiiDirector | Stock Award(Grant) at price 0.00 per share. | 35K | — |
| Jun 10, 2026 | Hoberman KennethDirector | Stock Award(Grant) at price 0.00 per share. | 35K | — |
| Jun 10, 2026 | Kaplan Matthew L.Director | Stock Award(Grant) at price 0.00 per share. | 35K | — |
| Jun 10, 2026 | Sanchez JuanDirector | Stock Award(Grant) at price 0.00 per share. | 35K | — |
| Jan 5, 2026 | Bentsur RonChief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 150K | — |
| Jan 5, 2026 | Shemesh ShayOfficer | Stock Award(Grant) at price 0.00 per share. | 150K | — |
| Jan 5, 2026 | Poradosu EnriqueOfficer | Stock Award(Grant) at price 0.00 per share. | 150K | — |
| Jan 5, 2026 | Carson Michael J.Officer | Stock Award(Grant) at price 0.00 per share. | 61.2K | — |
| Nov 4, 2025 | Bentsur RonChief Executive Officer | Purchase at price 5.72 per share. | 5K | $28.60K |
| Nov 4, 2025 | Kaplan Matthew L.Director | Purchase at price 5.84 per share. | 11K | $64.24K |
| Nov 4, 2025 | Sanchez JuanDirector | Purchase at price 5.79 per share. | 13K | $75.27K |
| Oct 26, 2025 | Mosseri Marlio CharlesBeneficial Owner of more than 10% of a Class of Security | Purchase at price 6.06 - 6.28 per share. | 154.8K | $957.08K |
| Sep 21, 2025 | Sanchez JuanDirector | Stock Award(Grant) at price 0.00 per share. | 30K | — |
| Jun 19, 2025 | Mosseri Marlio CharlesBeneficial Owner of more than 10% of a Class of Security | Purchase at price 7.99 per share. | 5.6K | $44.77K |
| Jun 17, 2025 | Mosseri Marlio CharlesBeneficial Owner of more than 10% of a Class of Security | Purchase at price 8.05 - 8.11 per share. | 33.4K | $269.53K |
| Jun 11, 2025 | Oliviero James F IiiDirector | Stock Award(Grant) at price 0.00 per share. | 30K | — |
| Jun 11, 2025 | Hoberman KennethDirector | Stock Award(Grant) at price 0.00 per share. | 30K | — |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 7.4 | 9.2 | -12.8 | 10.7 | 13.9 | 88.6 | 17.0 | 5.6 | -7.1 | -10.8 | +149.5% | ||
| 2025 | 25.0 | -1.0 | 46.0 | 1.9 | -5.5 | -20.6 | -6.8 | -5.7 | -8.2 | 11.5 | -7.0 | 21.0 | +39.6% |
| 2024 | -12.6 | 35.4 | -16.9 | -25.9 | 11.3 | -6.5 | 0.3 | 9.6 | -9.6 | 18.8 | -32.5 | 7.3 | −35.1% |
| 2023 | 32.3 | 15.2 | 14.7 | 12.9 | 18.2 | -8.7 | -12.0 | 1.9 | -9.9 | -30.6 | -5.0 | -1.9 | +11.2% |
| 2022 | 7.9 | 28.2 | 58.2 | -25.5 | -21.4 | -8.0 | -12.5 | -4.4 | 8.4 | 2.0 | +9.2% |
Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.
Buy / hold / sell counts